{"id":89213,"date":"2026-05-12T22:26:23","date_gmt":"2026-05-13T04:26:23","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=89213"},"modified":"2026-05-13T16:45:56","modified_gmt":"2026-05-13T22:45:56","slug":"cagrisema-results-timeline","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/cagrisema-results-timeline\/","title":{"rendered":"CagriSema Real Results: Weight Loss Timeline & What Patients Report"},"content":{"rendered":"

Introduction<\/h2>\n

CagriSema’s REDEFINE 1 phase 3 trial showed mean weight loss of about 22.7% at 68 weeks. That’s a headline number but it doesn’t capture the actual timeline patients experience. Weight loss isn’t linear. It accelerates during dose escalation, peaks during maintenance, and then slows as patients approach a new physiologic equilibrium. Some patients lose much more than the mean; others lose less. Individual variation is real and substantial.<\/p>\n

This article walks through the realistic trajectory based on REDEFINE 1, REDEFINE 2, and earlier phase 2 data, plus comparison data from STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide). The goal is to help patients set expectations for what each phase of treatment looks like and what the response rates are at various milestones. CagriSema isn’t yet FDA-approved, but the phase 3 data establishes the expected pattern.<\/p>\n

For patients currently on compounded semaglutide through TrimRx, the early titration experience is similar to what CagriSema will look like once approved. The cagrilintide component adds incremental weight loss during the later phases of treatment, particularly months 6-18.<\/p>\n

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n

What’s the Typical Weight Loss in the First Month?<\/h2>\n

Most patients lose 2-5 pounds in the first 4 weeks.<\/strong> This is on the 0.25 mg starter dose, which is intentionally subtherapeutic. The weight loss comes primarily from reduced caloric intake (3-5% reduction in total daily calories on average) and some fluid shifts as the GI system adapts. Visible body changes are minimal at this stage.<\/p>\n

Quick Answer: Mean weight loss at 68 weeks in REDEFINE 1: about 22.7%<\/p>\n

Some patients lose less than this; others lose more. Patients with higher starting BMI tend to lose more in absolute pounds because their baseline caloric needs are higher and the relative caloric reduction is larger in real terms. Patients who already eat at deficit before starting may lose less.<\/p>\n

The first month is more about adaptation than results. Side effects (nausea, occasional GI symptoms) are most common in this window. Patients who push through the first month typically have an easier time with subsequent titration steps.<\/p>\n

What Happens Between Months 2 and 4?<\/h2>\n

The 2-4 month window corresponds to titration steps 2 and 3 (0.5 mg and 1.0 mg of each component).<\/strong> Weight loss accelerates because the receptor activation is now meaningful. Patients lose roughly 1-2 pounds per week during this phase, with a typical cumulative loss of 8-15% from baseline by month 4.<\/p>\n

Appetite changes become noticeable. Many patients describe a clear reduction in food noise, smaller portions feeling sufficient, and reduced interest in hyperpalatable foods (chips, sweets, fried foods). Some patients struggle to eat enough during this phase because the appetite suppression is strong.<\/p>\n

This is also the phase where patients commonly start noticing physical changes: clothes fit differently, weight readings on the scale drop visibly, energy levels are typically maintained or improved. Photographs taken at month 1 vs month 4 show real differences for most patients.<\/p>\n

What Does the Maintenance Phase Look Like (Months 5-12)?<\/h2>\n

Once at maintenance dose (2.4 mg of each component), weight loss continues but slows.<\/strong> The typical rate drops to 0.5-1.5 pounds per week, gradually decreasing toward 0.25-0.5 pounds per week as month 12 approaches. Cumulative weight loss at month 12 in REDEFINE 1 was approximately 18-20% on average.<\/p>\n

Plateau periods are common during this phase. Patients may lose 5-7 pounds in a month, then nothing for 2-3 weeks, then resume losing. The pattern is normal and reflects metabolic adaptation to the new lower body weight. Resistance training and protein intake support continued progress through plateaus.<\/p>\n

Body composition changes accelerate during this phase. Waist circumference drops, visceral fat decreases more than subcutaneous fat in DEXA-tracked patients, and metabolic markers like fasting glucose, A1c, and triglycerides improve substantially. The medication’s cardiometabolic effects become clinically meaningful.<\/p>\n

When Does Weight Loss Start to Slow?<\/h2>\n

Most patients see meaningful slowdown around weeks 50-60.<\/strong> The REDEFINE 1 mean curve shows steady weight loss through week 50 with deceleration thereafter. By week 68, the trial endpoint, the rate has dropped to near zero for most patients. End-of-trial mean weight loss was 22.7%.<\/p>\n

The plateau happens because the body adapts to lower weight. Resting metabolic rate decreases, leptin levels drop, hunger signaling partially recalibrates, and the same caloric intake that produced weight loss earlier now matches new maintenance needs. This isn’t unique to CagriSema; it happens with all sustained weight loss.<\/p>\n

For patients still wanting more weight loss at the plateau, options include adding behavioral interventions (structured nutrition coaching, increased physical activity), considering combination with bariatric surgery in eligible patients, or accepting the achieved weight loss as the new equilibrium. Most patients are at or near their treatment goal by this stage.<\/p>\n

How Do Response Rates Differ Across Patients?<\/h2>\n

REDEFINE 1 response rates at 68 weeks for various weight loss thresholds:<\/p>\n